Retrospective Cohort Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Mar 15, 2023; 15(3): 523-532
Published online Mar 15, 2023. doi: 10.4251/wjgo.v15.i3.523
Risk of pancreatic cancer in individuals with celiac disease in the United States: A population-based matched cohort study
Arunkumar Krishnan, Yousaf Bashir Hadi, Sarah Shabih, Diptasree Mukherjee, Ruhee A Patel, Rushik Patel, Shailendra Singh, Shyam Thakkar
Arunkumar Krishnan, Yousaf Bashir Hadi, Sarah Shabih, Ruhee A Patel, Rushik Patel, Shailendra Singh, Shyam Thakkar, Section of Gastroenterology & Hepatology, West Virginia University School of Medicine, Morgantown, WV 26505, United States
Diptasree Mukherjee, Department of Medicine, Apex Institute of Medical Science, Kolkata 700075, West Bengal, India
Author contributions: Krishnan A conceptualized and designed the research and performed the formal analysis and interpretation of the data; Krishnan A and Hadi YB wrote the original draft and performed the review and editing of the draft; Krishnan A performed a critical revision of the manuscript; and all authors revised the manuscript for important intellectual content and approved the article’s final version, including the authorship list.
Institutional review board statement: TriNetX data have been granted a waiver from the Western institutional review board as a federated network since only aggregated counts and statistical summaries of de-identified information.
Informed consent statement: Not applicable for de-identified data.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE-Statement checklist of items, and the manuscript was prepared and revised according to the STROBE-Statement checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Arunkumar Krishnan, MBBS, Doctor, Section of Gastroenterology & Hepatology, West Virginia University School of Medicine, PO Box 9161, 5th Floor HSC, Room 5500, Morgantown, WV 26505, United States. dr.arunkumar.krishnan@gmail.com
Received: November 11, 2022
Peer-review started: November 11, 2022
First decision: November 28, 2022
Revised: December 8, 2022
Accepted: February 10, 2023
Article in press: February 10, 2023
Published online: March 15, 2023
Processing time: 123 Days and 10.2 Hours
Abstract
BACKGROUND

Celiac disease (CD) has been associated with gastrointestinal malignancies. However, the magnitude of the risk of pancreatic cancer (PC) associated with CD is much less clear, and risks have not been estimated from large populations.

AIM

To assess the risk of PC in CD patients.

METHODS

We conducted a population-based, multicenter, propensity score-matched cohort study with consecutive patients diagnosed with CD using the TriNeTx research network platform. We examined the incidence of PC in patients with CD compared with a matched cohort of patients without CD (non-CD, controls). Each patient in the main group (CD) was matched to a patient in the control group using 1:1 propensity score matching to reduce confounding effects. The incidence of PC was estimated using a Cox proportional hazards model with a hazard ratio (HR) and 95% confidence interval (CI).

RESULTS

A total of 389980 patients were included in this study. Among them, 155877 patients had a diagnosis of CD, and the remaining 234103 individuals without CD were considered a control cohort. The mean duration of follow-up for patients in the CD and control cohorts was 5.8 ± 1.8 and 5.9 ± 1.1 years, respectively. During the follow-up, 309 patients with CD developed PC, whereas 240 patients developed PC in the control group (HR = 1.29; 95%CI: 1.09-1.53). In the secondary analyses in the first year after diagnosis of CD, patients with CD were at a significant increase in risk for PC; 151 patients with CD had an incidence of PC compared with 96 incidences of PC among the patients in the non-CD control group (HR = 1.56; 95%CI: 1.20-2.01) and sensitivity analysis showed similar magnitude to the one generated in the primary and secondary analysis.

CONCLUSION

Patients with CD are at increased risk of PC. Risk elevation persists beyond the first year after diagnosis to reference individuals without CD from the general population.

Keywords: Celiac disease; Cancer; Epidemiology; Pancreas; Pancreatic cancer; Malignancy; Carcinoma

Core Tip: Celiac disease (CD) is an immune-mediated disorder precipitated by the ingestion of gluten in genetically predisposed individuals. Population-based studies have shown the risk of cancer among patients with CD; however, the magnitude of the risk of pancreatic cancer (PC) in association with CD is much less clear. Therefore, In this multicenter retrospective cohort study, we analyzed the risk of PC in patients with CD. We examined the incidence of PC in patients with CD compared with a propensity-matched cohort of patients without CD. We found that patients with CD were at increased risk of PC. Risk elevation persisted beyond the first year after diagnosis to reference individuals without CD from the general population.